1. Introduction {#sec1}
===============

Loss to followup (LTFU) in patients receiving antiretroviral therapy can cause serious consequences such as discontinuation of treatment and increased risk of death \[[@B1]--[@B3]\]. At a program level, LTFU can make it difficult to evaluate outcomes of treatment and care \[[@B4], [@B5]\]. In resource-limited settings, where treatment has become rapidly available following the rollout of antiretroviral therapy, LTFU presents even more challenging obstacles that require special consideration and approaches \[[@B6], [@B7]\].

One of the key questions in patient followup is how to define a patient as LTFU. This has varied in studies conducted in different settings \[[@B8]--[@B10]\]. Defining LTFU using a very early threshold, for example, a patient with no clinic visit in the last three months, may result in many patients being considered as LTFU who would return to clinic naturally at a later date. Defining LTFU with a long threshold, for example, one year, may mean delaying too long before any effort is made to track patients potentially at risk of LTFU.

The majority of research into LTFU in HIV-infected patients receiving antiretroviral treatment in resource-limited settings has been conducted in the sub-Saharan Africa region \[[@B3], [@B10]--[@B13]\]. A few studies have been conducted among Asian, mostly female, patients \[[@B14]--[@B16]\]. Using data from the TREAT Asia HIV Observational Database (TAHOD), this study was carried out to find the best-performing definition of LTFU and examine the characteristics of HIV-infected patients from the Asia-Pacific who were LTFU from treatment and care.

2. Methods {#sec2}
==========

Established in 2003, TAHOD is a collaborative observational cohort study involving 18 sites in the Asia-Pacific region (see Acknowledgement). Detailed methods have been published previously \[[@B17]\]. Briefly, each site recruited approximately 200--300 HIV-infected patients, with recruitment based on a consecutive series of patients regularly attending a given site from a particular start-up time. Ethical approval for the study was obtained from the University of New South Wales Ethics Committee, Western Institutional Review Board, and respective local ethics committee from each TAHOD participating site.

The following data were collected: patient demographics and baseline data, CD4 and CD8 count, HIV viral load, prior and new AIDS defining illness (ADI), date and cause of death, prior and current prescribed antiretroviral treatment (ART), and reason for treatment change. Data were collected according to a common protocol. Upon recruitment, all available data prior to entry to TAHOD (considered as retrospective data) were extracted from patient case notes. Prospective data were updated six-monthly at each clinic and transferred to the data management centre for aggregation and analyses in March and September each year. TAHOD sites were encouraged to contact patients who have not been seen in the clinics in the previous 12 months.

TAHOD data submitted at March 2009 and March 2010 were used to find the best-performing definition of LTFU. TAHOD patients who had no followup after recruitment were not included in this analysis. Patients who were not seen in clinic for more than 12 months prior to the March 2010 data submission (i.e., last clinic visit prior to March 2009) were considered to be truly LTFU. The days between the last clinical visit and 31 March 2009 in the March 2009 data transfer were then used to find the interval that best classified a true LTFU in the following way. A series of cutoffs were considered, from ten to 365 days, to define patients as potentially LTFU. Each of these definitions of potential LTFU was compared with the gold standard of true LTFU, defined as no patient followup in the 12 months prior to 31 March 2010. The sensitivity and specificity of each cutoff in identifying true LTFU were calculated, and the best performing cutoff identified using the area under the receiver operator characteristic (ROC) curve. The optimal definition of LTFU identified in terms of maximising the sensitivity and specificity of true LTFU was found to be 180 days (see Results). This definition was then used in the risk factor analyses that follow.

Followup started from the last clinic visit at the March 2007 data submission. Patients who were considered LTFU before March 2007 (i.e., had no clinic visits 180 days before 31 March 2007) were excluded from the analysis. For patients enrolled after March 2007, the followup started at the time of enrolment. In terms of calculating person-years of followup, the end of followup for patients who had no clinic visit for 180 days and so were considered as LTFU was defined as 90 days after their last clinic visit. For patients not considered LTFU, the end of followup was also defined as 90 days after their last clinic visit. If a patient died, the followup was censored on the date of death if the date was within 180 days of their last clinic visit. Patients who died after March 2007 were considered to have complete followup. It should be noted that patients who were considered LTFU could return to clinic and reenter followup. The start of this reentry to followup was defined as 3 months prior to the first clinic visit that reinitiated followup. The patients that reentered followup could also be re-LTFU if the patient subsequently did not attend clinic for more than 180 days. The definitions we adopted were consistent with those in a previous study \[[@B18]\].

The rates of LTFU were calculated by the number of total LTFU periods divided by the total duration of followup contributed by the patients included in the analysis \[[@B18]\]. Because of the reentering and re-LTFU, patients could contribute more than one episode of LTFU in this analysis. The rates were further calculated in different strata, including age, sex, exposure category, hepatitis B and C infection, year since HIV infection, calendar year, the latest CD4 count and viral load, antiretroviral treatment status, CDC disease stages, prophylaxis (coded as receiving or not), and haemoglobin level, all taken at the start of each episode.

Factors associated with LTFU were assessed by multivariate Poisson regression models, using generalised estimating equations, to allow for multiple events of LTFU in the same patients. CD4 count, HIV viral load, antiretroviral treatment, AIDS diagnosis, and haemoglobin tests were included as time-dependent variables and updated at the time the new measurement or diagnosis was available.

Patients who had at least one episode of LTFU were then categorised into two groups: those who had no more clinical visits in the database (permanently LTFU) and those who later reentered followup (temporary LTFU). Multivariate logistic regression models were used to compare the characteristics in patients who were considered permanently LTFU with those who were temporary LTFU. All covariates were taken at the end of the episode in patients with truly LTFU or at the end of the first episode in patients considered temporary LTFU.

Multivariate models were built using a forward-stepwise approach. The final model included covariates that remained significant at the *P* \< 0.05 level. Nonsignificant variables were also presented and adjusted for the final multivariate models. Data management and statistical analyses were performed using SAS for Windows (SAS Institute Inc., Cary, NC, USA) and Stata (StataCorp, STATA 10.1 for Windows, College Station, TX, USA).

3. Results {#sec3}
==========

In March 2007, there were 2565 patients in the database. 1061 patients were subsequently enrolled in TAHOD up to March 2010. A total of 3626 patients from TAHOD who had follow-up visits in the clinic were included in this analysis. During the study period (from March 2007 to March 2010), there were 54 patients who died and considered to have complete followup.

Using days between last clinic visit and 31 March 2009 in the March 2009 data transfer, we identified the interval that best classifies a true LTFU (i.e., no clinic visit after 31 March 2009). An interval of 180 days was determined as the best-performing definition ([Table 1](#tab1){ref-type="table"}, sensitivity 90.6%, specificity 92.3%). Using 180 days as the LTFU cutoff, during 7697 person-years of followup, a total of 1648 episodes of LTFU from 1298 patients were identified, giving a crude LTFU rate of 21.4 per 100 person-years (95% confidence interval, CI, 20.4 to 22.5). Of those 1648 episodes of LTFU identified using 180 days as the cutoff, 48% were considered permanently LTFU (i.e., the patient did not return to clinic before 31 March 2010), corresponding to 45% of the 1298 patients.

The patient characteristics are summarised in [Table 2](#tab2){ref-type="table"}. The majority of patients were male (71%), aged between 36 and 45 years (40%), and reported heterosexual transmission (64%). Chinese (27%), Thai (26%), and Indian (11%) were the main ethnic groups. At recruitment, approximately 12% did not have a CD4 count test, and of those tested, the majority had a CD4 count more than 200 cells/*μ*L. Nearly half (45%) did not have an HIV viral load test, and of those tested, the majority were below 500 copies/mL. Close to half of the patients (46%) were diagnosed with an AIDS defining illness at recruitment, with tuberculosis being the main illness. Most patients (63%) had been reported to be diagnosed with HIV for less than 6 years when recruited to TAHOD (measured as the time from first reported positive HIV test). Less than 10% of the patients were coinfected with either hepatitis B or hepatitis C. At recruitment, the majority of patients had normal haemoglobin level. At the start of study followup, most of the patients were on antiretroviral therapy including three or more drugs in combination including at least one nucleoside reverse transcriptase inhibitor (NRTI) and one nonnucleoside reverse transcriptase inhibitor. Over 20% of patients were in a combination with at least one NRTI and a protease inhibitor (PI). All patients were receiving, or started, antiretroviral therapy during followup.

[Table 3](#tab3){ref-type="table"} summarises univariate and multivariate analyses of factors associated with LTFU using 180 days as cut-off. In univariate analyses, the rate of LTFU was significantly lower in patients with a current CD4 counts above 200 cells/*μ*L compared to patients with a CD4 count less than 100 cells/*μ*L, but this was not significant in the final multivariate model. In the final multivariate model ([Table 3](#tab3){ref-type="table"}), factors associated with LTFU included age (younger patients had higher rate of LTFU), current HIV viral load (either patients with HIV viral load ≥500 copies/mL or no tests in recent 180 days had higher rate of LTFU), history of HIV infection (patients with shorter history of HIV infection had higher rate of LTFU), hepatitis C infection (patients with positive hepatitis C antibody had higher rate of LTFU), and, finally, current combination of antiretroviral treatment (compared to patients on triple-drug regimen with at least one NRTI and one NNRTI, patients receiving no-, single-, or double-drug antiretroviral therapy, or a triple-drug regimen containing at least one NRTI and one PI, had higher rate of LTFU).

[Table 4](#tab4){ref-type="table"} shows factors that predict permanent LTFU among patients who had no clinic visit for 180 days and so met our optimal definition of LTFU. In the final multivariate model, patients permanently LTFU were more likely to be older, have not been anemic, have no recent HIV viral load test, have tested negative for hepatitis C infection or have never tested for hepatitis C, and have had more than one episode of previous temporary LTFU.

4. Discussion {#sec4}
=============

We found that an interval of 180 days between clinic visits was the best-performing definition of LTFU based on sensitivity and specificity in identifying true LTFU. By this definition, we observed that approximately one in five patients in our cohort would miss clinic visits for more than 180 days and so become defined as LTFU. Among these patients in our cohort close to half eventually returned to followup, with half becoming truly lost to HIV-related treatment and care.

The 180-day cutoff has been used by other studies as a working definition of LTFU \[[@B10], [@B19]--[@B21]\]. Other intervals have also been proposed as measurements of classifications of LTFU, such as 90 days \[[@B8]\] and 365 days \[[@B9]\]. Regional- and cohort-dependent characteristics, such as scheduled clinic visits, patient burden, and drug availability could result in specific intervals that best categorise patients at risk of LTFU. Nevertheless, a 180-day (or 6-month) cutoff is an appealing and easy-to-apply definition that could be used in different clinical settings in the Asia-Pacific region to flag patients at risk of being permanently lost to treatment and care. Our analyses suggest patients with no clinic visits for six months are at high risk of being permanently lost and should be aggressively traced.

Chi et al. also found that a cutoff of 180 days was optimal to define LTFU after analysing data from the Africa, Asia, and Latin America regions of the IeDEA collaboration (including data from our cohort) \[[@B22]\]. There are some methodological differences between our analyses, principally regarding minimum numbers of patients for site inclusion. Chi et al. found quite extensive heterogeneity between sites, something we also found to a lesser extent. However, it is nevertheless reassuring that we found a similar optimal cutoff of 180 days without clinic visits to define LTFU. With rapid scaling up of antiretroviral treatment taking place globally, there is a need to adopt a universal consistent definition of LTFU, or a general algorithm to define cutoffs, to evaluate HIV treatment programs in different regions \[[@B6], [@B7], [@B19]\].

Over one in five patients in our cohort failed to come to clinic for more than 180 days in a given year. Similar rates have also been found in patients from Africa \[[@B3], [@B11]\]. However, the LTFU rate was lower in EuroSIDA \[[@B23]\], a large prospective cohort study with HIV-infected patients mainly from Europe (using one year as a cutoff). Approximately half of the patients who experienced LTFU in our study later came back to clinic, and patients who had a previous episode of LTFU were more likely to prove to be true LTFU, similar to previous findings \[[@B18]\].

We found that younger patients, patients infected with hepatitis C, and patients with detectable or unmeasured viral load were more likely to experience LTFU. These findings are all consistent with previous study findings \[[@B10], [@B11], [@B24]--[@B26]\]. Patients with undetectable viral load are likely to be motivated and adherent to antiretroviral treatment and thus remain in care. Among those patients who experienced LTFU, we found that those who tested negative for hepatitis C infection or were never tested for hepatitis C were more likely to be permanently LTFU. This finding seems counterintuitive, but it might be that patients who have tested positive for hepatitis C receive more medical attention from their clinicians and thus prove less likely to be permanently LTFU. Among patients identified as LTFU, anemic patients were also more likely to be permanently lost to treatment and care. Anemia has been shown to be a strong prognostic marker for HIV disease progression and survival \[[@B27]\], which could, at least in part, explain these patients failing to return to followup.

Compared to patients on NNRTI-based regimen, patients receiving no-, single-, or double-drug antiretroviral therapy or a triple-drug regimen containing PI were more likely to experience LTFU. The reasons for this are not clear. The greater loss to followup may be associated with increased drug toxicity, either resulting in a patient receiving mono- or dual therapy or from receiving a PI. Patients receiving PI-based regimens are also those who are more likely to be on a second line regimen, a regimen that may be substantially more expensive than first line. In the Asia Pacific region, out-of-pocket expenses are needed to pay for treatment in some clinics. Hence, the lost to followup may be associated with drug availability or affordability. It is worth noting that patients receiving mono- or dual therapy, or a PI based regimen, were also associated with being less likely to be permanently lost to followup, that is to say more likely to return to clinic (albeit not quite statistically significantly so). This possibly supports the idea of these regimens being associated with short-term drug availability or affordability issues. Unfortunately, data are not available to address this issue in any greater detail.

It has been shown that, in resource-limited settings, predominantly in Africa, patients who are LTFU have a much poorer prognosis than patients who remain in followup \[[@B5]\]. In part, this is due to a proportion of patients who die not having vital status information updated at their treatment site. The extent to which this occurs in TAHOD is uncertain. While it seems likely that at least some patients who are LTFU have died without this information reaching the site, the lack of association between key measures of HIV disease progression, such as CD4 count and AIDS defining illnesses, and LFTU suggests it may be lower than in African settings. However, this association between LTFU and poorer prognosis underpins the need for consistent definitions of LTFU in research cohort studies, and where there are possible active patient tracing strategies or at least sampling-based approaches \[[@B28]\] to ensure comparability of results across studies and settings.

Several limitations should be considered in interpreting the results in this paper. First, TAHOD participating sites are generally urban referral centres, and the patients recruited in TAHOD were those regularly attending a given TAHOD site. Hence, TAHOD patients are not representative of all HIV-infected patients in the Asia and Pacific region. The overall rate of LTFU we saw in our study is therefore likely to be an underestimate of rates across the region. However, the effect of these sampling biases on the optimal definition of LTFU and on the covariate analyses is arguably less strong. It is reassuring that our estimate of the optimal definition of LTFU is consistent with that seen across Africa and Latin America \[[@B22]\]. Second, since antiretroviral treatment has become more decentralised and available in distant or rural communities with rapid scale-up programs, patients might choose to receive treatment and care locally rather than at tertiary and referral centres \[[@B29], [@B30]\]. Consequently, patients may have been retained in care but not necessarily in the clinics involved in this study. Information on referral to other health facility was only recently included in the data collection, so we could not further verify if patients were retained in care or truly loss to health services. Third, we do not collect data on the measures TAHOD sites undertake to routinely trace patients who are LTFU. These measures differ across sites according to local practices and conditions. Effective patient tracking and recording are essential to program evaluation and maintenance of treatment and care \[[@B1], [@B18]\]. What patient tracking measures are effective in retaining patients in treatment and care in the Asia-Pacific region is an area that deserves further research. We also do not have data on transportation \[[@B31]\], social and economic status \[[@B32]\], pregnancy for women \[[@B10]\], and community support \[[@B33]\], all of which have been found to be important determinants of LTFU. Lastly, the patients included in this study were all receiving, or started, antiretroviral treatment and had clinical assessments. Consequently, the results cannot be extrapolated to patients not yet initiated on antiretroviral therapy. Research into followup among HIV-infected patients not receiving antiretroviral treatment in the Asia-Pacific region needs to be considered \[[@B34]--[@B36]\], particularly in the context of the move to start treatment earlier.

5. Conclusion {#sec5}
=============

With rapid scaleup of antiretroviral treatment, it is essential to study factors that predict loss to followup and identify patients at risk of loss to treatment and care, particularly in resource-limited settings. At the treatment and care level, this can maintain efficacy of antiretroviral therapy and avoid adverse events. At the program evaluation level, the impact of loss to followup on overall treatment outcome, disease progression, and survival can then be accounted for with appropriate statistical adjustments. Collaboration with HIV treatment programs in other regions in studies on LTFU and in particular standardisation of LTFU definitions are essential for reporting and program evaluation.
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###### 

Receiver operating characteristic (ROC) analysis for the best-performing definition for loss to followup.

  Cutoff (days)   Sensitivity (%)   Specificity (%)   Area under ROC   Cutoff (days)   Sensitivity (%)   Specificity (%)   Area under ROC
  --------------- ----------------- ----------------- ---------------- --------------- ----------------- ----------------- ----------------
  10              99.67             16.97             58.32            160             90.96             90.77             90.87
  20              99.02             24.32             61.67            170             90.64             91.44             91.04
  30              98.05             31.31             64.68            175             90.64             92.05             91.34
  40              96.82             39.90             68.36            **180**         **90.55**         **92.26**         **91.41**
  50              96.34             49.52             72.93            185             90.23             92.53             91.38
  60              95.77             57.20             76.48            190             89.33             93.01             91.17
  70              95.28             65.52             80.40            200             88.52             93.44             90.98
  80              95.11             71.26             83.19            210             87.79             94.13             90.96
  90              94.71             77.62             86.16            240             85.26             95.25             90.26
  100             94.22             80.91             87.57            270             83.55             96.43             89.99
  120             93.24             86.18             89.71            300             82.00             97.04             89.52
  150             91.53             90.17             90.85            365             78.99             97.73             88.36

True LTFU defined as no patient followup in the 12 month prior to 31 March 2010. Each cutoff used as a potential definition of LTFU was the days between last clinical visit and 31 March 2009 in the March 2009 data transfer. The sensitivity and specificity of each cutoff in identifying true LTFU were calculated, and the optimal cutoff identified based on ROC analysis.

###### 

Patient characteristics.

  Total                                  3626   
  -------------------------------------- ------ ----
  Sex                                           
   Male                                  2567   71
   Female                                1059   29
                                                
  Current age (years)                           
  ≤35                                    1383   38
  36--45                                 1449   40
  46+                                    794    22
                                                
  Reported exposure                             
   Heterosexual contact                  2337   64
   Homosexual contact                    749    21
   Injecting drug use                    263    7
   Other/unknown                         277    8
                                                
  Ethnicity                                     
   Chinese                               989    27
   Indian                                390    11
   Thai                                  933    26
   Other/unknown                         1314   36
                                                
  Baseline CD4 count (cells/*μ*l.)              
   ≤100                                  239    7
   101--200                              406    11
   201+                                  2531   70
   Missing                               450    12
                                                
  Baseline HIV RNA (copies/ml)                  
   ≤500                                  1482   41
   501+                                  379    10
   Missing                               1765   49
                                                
  CDC disease stage at baseline                 
   Stage A                               1621   45
   Stage B                               321    9
   Stage C                               1684   46
                                                
  Tuberculosis diagnosis at baseline            
   No                                    2758   76
   Yes                                   868    24
                                                
  Time since HIV infection (years)              
   ≤5                                    2295   63
   6+                                    1246   34
   Missing                               85     2
                                                
  Hepatitis B infection                         
   No                                    2297   63
   Yes                                   257    7
   Not tested                            1072   30
                                                
  Hepatitis C infection                         
   No                                    2007   55
   Yes                                   324    9
   Not tested                            1295   36
                                                
  Anemia at baseline                            
   No                                    2480   68
   Yes                                   597    16
  Haemoglobin not tested                 567    16
  Antiretroviral treatment at baseline          
   3 + (NRTI + NNRTI)                    2224   61
   3 + (NRTI + PI)                       744    21
   No/mono/double drug                   583    16
   3 + (other combination)               75     2

Anemia: haemoglobin \<13 g/dl (male), \<11 g/dl (female); NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor.

###### 

Factors associated with permanent or temporary LTFU, defined as no clinic visit for 180 days, among all patients under followup.

                                                        Person- years   Number LTFU   Crude Rate^1^   Adjusted                                                               
  ----------------------------------------------------- --------------- ------------- --------------- ---------------- ------ -------------- --------- ------ -------------- ----------
  Sex                                                                                                                                                                        
   Male                                                 5468.1          1206          22.06           (20.85, 23.34)   1.00                            1.00                  
   Female                                               2229.2          442           19.83           (18.06, 21.77)   1.10   (0.98, 1.24)   0.090     1.04   (0.93, 1.17)   0.446
                                                                                                                                                                             
  Current age (years)                                                                                                                                                        
   ≤35                                                  2210.4          575           26.01           (23.97, 28.23)   1.00                            1.00                  0.002^3^
   36*∼*45                                              3320.2          718           21.62           (20.10, 23.27)   0.82   (0.74, 0.92)   0.001     0.89   (0.79, 1.00)   0.050
   46+                                                  2166.6          355           16.39           (14.77, 18.18)   0.69   (0.60, 0.79)   \<0.001   0.76   (0.66, 0.88)   \<0.001
                                                                                                                                                                             
  Reported exposure                                                                                                                                                          
   Heterosexual  contact                                5144.5          985           19.15           (17.99, 20.38)   1.00                            1.00                  
   Homosexual  contact                                  1707.2          344           20.15           (18.13, 22.40)   1.10   (0.93, 1.29)   0.275     1.05   (0.89, 1.25)   0.540
   Injecting drug use                                   344.3           125           36.31           (30.47, 43.27)   1.21   (0.97, 1.51)   0.098     1.10   (0.86, 1.40)   0.437
   Other/unknown                                        501.3           194           38.70           (33.62,44.55)    1.64   (1.37, 1.98)   \<0.001   1.56   (1.29, 1.88)   \<0.001
                                                                                                                                                                             
  Current CD4 count (cells/*μ*l.)                                                                                                                                            
   ≤100                                                 233.7           69            29.52           (23.32, 37.38)   1.00                            1.00                  
   101--200                                             635.7           136           21.40           (18.09, 25.31)   0.92   (0.68, 1.22)   0.551     0.96   (0.72, 1.29)   0.800
   201+                                                 6327.6          1181          18.66           (17.63, 19.76)   0.75   (0.58, 0.96)   0.023     0.79   (0.61, 1.02)   0.071
   Missing                                              500.3           262           52.37           (46.40, 59.11)   1.18   (0.90, 1.55)   0.235     0.99   (0.74, 1.31)   0.922
                                                                                                                                                                             
  Current HIV RNA (copies/ml)                                                                                                                                                
   ≤500                                                 4213.7          679           16.11           (14.95, 17.37)   1.00                            1.00                  0.021^3^
   501+                                                 537.1           158           29.42           (25.17, 34.38)   1.71   (1.43, 2.04)   \<0.001   1.24   (1.03, 1.51)   0.026
   Missing                                              2946.4          811           27.52           (25.69, 29.49)   1.75   (1.55, 1.98)   \<0.001   1.64   (1.45, 1.86)   \<0.001
                                                                                                                                                                             
  CDC disease stage                                                                                                                                                          
   Stage A                                              3205.1          828           25.83           (24.13, 27.65)   1.00                            1.00                  
   Stage B                                              801.6           118           14.72           (12.29, 17.63)   0.93   (0.76, 1.14)   0.507     0.95   (0.77, 1.17)   0.623
   Stage C                                              3690.5          702           19.02           (17.67, 20.48)   0.84   (0.75, 0.93)   0.001     0.92   (0.82, 1.02)   0.125
                                                                                                                                                                             
  Tuberculosis diagnosis                                                                                                                                                     
   Yes                                                  1806.7          372           20.59           (18.60, 22.79)   1.00                            1.00                  
   No                                                   5890.6          1276          21.66           (20.51, 22.88)   1.04   (0.92, 1.18)   0.537     0.98   (0.87, 1.12)   0.801
                                                                                                                                                                             
  Time since HIV infection (years)                                                                                                                                           
   ≤5                                                   3477.2          785           22.58           (21.05, 24.21)   1.00                            1.00                  0.005^3^
   6+                                                   4115.7          844           20.51           (19.17, 21.94)   0.84   (0.75, 0.94)   0.002     0.89   (0.79, 1.00)   0.048
   Missing                                              104.3           19            18.21           (11.61, 28.55)   0.58   (0.36, 0.94)   0.027     0.49   (0.30, 0.79)   0.004
                                                                                                                                                                             
  Hepatitis B infection                                                                                                                                                      
   Yes                                                  584.5           112           19.16           (15.92, 23.06)   1.00                            1.00                  
   No                                                   5101.9          883           17.31           (16.20, 18.49)   0.93   (0.76, 1.13)   0.474     0.90   (0.74, 1.10)   0.319
   N/A                                                  2010.8          653           32.48           (30.08, 35.06)   0.98   (0.80, 1.21)   0.859     1.07   (0.85, 1.35)   0.548
                                                                                                                                                                             
  Hepatitis C infection                                                                                                                                                      
   Yes                                                  541.4           149           27.52           (23.44, 32.31)   1.00                            1.00                  0.030^3^
   No                                                   4692.8          796           16.96           (15.82, 18.18)   0.81   (0.67, 0.98)   0.029     0.81   (0.67, 0.98)   0.034
   N/A                                                  2463.0          703           28.54           (26.51, 30.73)   0.75   (0.62, 0.91)   0.004     0.77   (0.63, 0.93)   0.008
  Current anemia (male \< 13 g/dl, female \< 11 g/dl)                                                                                                                        
   Yes                                                  1021.1          155           15.18           (12.97, 17.77)   1.00                            1.00                  
   No                                                   5771.6          1157          20.05           (18.92, 21.24)   1.09   (0.92, 1.30)   0.302     1.11   (0.94, 1.32)   0.227
   N/A                                                  904.5           336           37.15           (33.38, 41.34)   1.31   (1.07, 1.59)   0.008     1.09   (0.89, 1.34)   0.382
  Current ART^4^                                                                                                                                                             
   3 + (NRTNRTI)                                        4830.8          942           19.50           (18.29, 20.79)   1.00                            1.00                  0.001^3^
   3 + (NRTI + PI)                                      1898.3          377           19.86           (17.95, 21.97)   1.21   (1.06, 1.38)   0.005     1.22   (1.07, 1.39)   0.003
   No/mono/double ARV                                   762.7           300           39.33           (35.12, 44.05)   2.18   (1.90,2.50)    \<0.001   1.92   (1.66, 2.22)   \<0.001
   3 + (other combination)                              205.4           29            14.12           (9.81, 20.32)    0.95   (0.65, 1.38)   0.786     1.01   (0.69, 1.47)   0.975

\(1\) Crude rate, per 100 person-years.

\(2\) Stratified by TAHOD sites.

\(3\) Overall for test for trend (ordinal categorical covariates) or for homogeneity (nominal categorical covariates).

\(4\) ART: NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor.

###### 

Factors that predict permanent LTFU in patients without a clinic visit for 180 days.

                                                        Number   True loss   \%     OR^1^   95% CI           *P* value   Adjusted OR^1^   95% CI           *P* value
  ----------------------------------------------------- -------- ----------- ------ ------- ---------------- ----------- ---------------- ---------------- ------------
  Sex                                                                                                                                                      
   Male                                                 1206     584         48.4   1.00                                 1.00                              
   Female                                               442      209         47.3   0.89    (0.69, 1.15)     0.359       0.80             (0.61, 1.05)     0.104
                                                                                                                                                           
  Current age (years)                                                                                                                                      
   ≤35                                                  568      278         48.9   1.00                                 1.00                              0.097^2^
   36*∼*45                                              717      340         47.4   1.33    (1.03, 1.71)     0.031       1.31             (1.00, 1.72)     0.050
   46+                                                  363      175         48.2   1.27    (0.94, 1.72)     0.118       1.28             (0.93, 1.77)     0.128
                                                                                                                                                           
  Reported exposure                                                                                                                                        
   Heterosexual contact                                 985      443         45.0   1.00                                 1.00                              
   Homosexual contact                                   344      199         57.8   1.12    (0.78, 1.60)     0.532       1.24             (0.85,1.81)      0.262
   Injecting drug use                                   125      55          44.0   1.01    (0.59, 1.73)     0.969       1.32             (0.72, 2.41)     0.364
   Other/unknown                                        194      96          49.5   1.07    (0.69, 1.64)     0.773       1.22             (0.78, 1.93)     0.382
                                                                                                                                                           
  Current CD4 count (cells/*μ*l.)                                                                                                                          
   ≤100                                                 58       36          62.1   1.00                                 1.00                              
   101--200                                             129      66          51.2   0.76    (0.36, 1.60)     0.471       0.99             (0.47, 2.13)     0.989
   201+                                                 1068     465         43.5   0.62    (0.33, 1.18)     0.144       0.82             (0.42, 1.59)     0.551
   Missing                                              393      226         57.5   1.50    (0.77, 2.93)     0.238       1.18             (0.58, 2.42)     0.649
                                                                                                                                                           
  Current HIV RNA (copies/mL)                                                                                                                              
   ≤500                                                 598      230         38.5   1.00                                 1.00                              0.011^2^
   501+                                                 153      78          51.0   1.02    (0.68, 1.52)     0.924       0.94             (0.62, 1.42)     0.767
   Missing                                              897      485         54.1   2.13    (1.63, 2.80)     \<0.001     1.54             (1.13, 2.09)     0.006
                                                                                                                                                           
  CDC disease stage                                                                                                                                        
   Stage A                                              828      413         49.9   1.00                                 1.00                              
   Stage B                                              121      54          44.6   0.77    (0.48, 1.22)     0.258       0.70             (0.43, 1.14)     0.154
   Stage C                                              699      326         46.6   1.00    (0.78, 1.27)     0.975       1.05             (0.81, 1.36)     0.702
                                                                                                                                                           
  Tuberculosis diagnosis                                                                                                                                   
   Yes                                                  361      186         51.5   1.00                                 1.00                              
   No                                                   1287     607         47.2   0.87    (0.66, 1.16)     0.342       0.85             (0.63, 1.15)     0.297
                                                                                                                                                           
  Time since HIV infection (years)                                                                                                                         
   ≤5                                                   771      400         51.9   1.00                                 1.00                              
   6+                                                   858      389         45.3   1.25    (0.98, 1.60)     0.076       1.03             (0.79, 1.34)     0.835
   Missing                                              19       4           21.1   0.37    (0.12, 1.17)     0.091       0.43             (0.13, 1.43)     0.170
                                                                                                                                                           
  Hepatitis B infection                                                                                                                                    
   Yes                                                  112      47          42.0   1.00                                 1.00                              
   No                                                   883      431         48.8   1.30    (0.84, 2.03)     0.243       1.35             (0.84, 2.16)     0.222
   N/A                                                  653      315         48.2   1.31    (0.82, 2.09)     0.253       1.03             (0.60,1.76)      0.908
  Hepatitis C infection                                                                                                                                    
   Yes                                                  149      66          44.3   1.00                                 1.00                              0.004^2^
   No                                                   796      376         47.2   1.57    (1.01, 2.45)     0.046       1.66             (1.04, 2.66)     0.034
   N/A                                                  703      351         49.9   1.96    (1.26, 3.05)     0.003       2.16             (1.35, 3.46)     0.001
                                                                                                                                                           
  Current anemia (male \< 13 g/dL, female \< 11 g/dL)                                                                                                      
   Yes                                                  141      87          61.7   1.00                                 1.00                              \<0.001^2^
   No                                                   1065     456         42.8   0.53    (0.35, 0.81)     0.003       0.50             (0.32, 0.76)     0.001
   N/A                                                  442      250         56.6   1.15    (0.73, 1.81)     0.549       0.78             (0.49, 1.26)     0.310
                                                                                                                                                           
  Current ART\*\*                                                                                                                                          
   3 + (NRTI + NNRTI)                                   911      404         44.3   1.00                                 1.00                              
   3 + (NRTI + PI)                                      356      167         46.9   0.76    (0.57, 1.02)     0.072       0.74             (0.54,1.01)      0.057
   No/mono/double ARV                                   352      209         59.4   0.93    (0.69, 1.26)     0.644       0.78             (0.57, 1.08)     0.137
   3 + (other combination)                              29       13          44.8   0.89    (0.40, 1.98)     0.770       0.85             (0.38, 1.94)     0.707
  Previous episode of temporary LTFU                                                                                                                       
   None                                                 1298     589         45.4   1.00                                 1.00                              \<0.001^2^
   Once                                                 296      158         53.4   2.79    (2.05, 3.80)     \<0.001     2.71             (1.97, 3.72)     \<0.001
   Twice                                                54       46          85.2   31.76   (13.91, 72.52)   \<0.001     27.75            (12.03, 64.01)   \<0.001

\(1\) Stratified by TAHOD sites.

\(2\) Overall for test for trend (ordinal categorical covariates) or for homogeneity (nominal categorical covariates).

\(3\) ART: NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor.

[^1]: Academic Editor: Anthony Harries
